S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,265.84 (-0.52%)
DOW   33,309.53 (-0.59%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
NASDAQ:STIM

Neuronetics (STIM) Stock Forecast, Price & News

$1.28
-0.07 (-4.81%)
(As of 02:33 PM ET)
Compare
Today's Range
$1.26
$1.36
50-Day Range
$1.29
$2.02
52-Week Range
$1.25
$6.95
Volume
86,897 shs
Average Volume
186,519 shs
Market Capitalization
$37.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Neuronetics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
639.3% Upside
$9.50 Price Target
Short Interest
Healthy
1.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$32,409 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.13) to ($0.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

171st out of 969 stocks

Surgical & Medical Instruments Industry

26th out of 100 stocks


STIM stock logo

About Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

STIM Price History

STIM Stock News Headlines

Board Member of Neuronetics Purchased $51K In Stock
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Cannell Capital Now Owns 8.45% of Neuronetics
Cannell Capital LLC Reduces Stake in Neuronetics Inc
Warren Buffett: Stark Warning On Inflation
According to a recent letter to Berkshire Hathaway shareholders, “Billionaire Investment Guru Warren Buffett issues stark inflation warning”. The new numbers have shown a comeback for inflation, surging to its highest levels in six months, and it’s now looking like there’s little chance our policy makers can put this cat back in the bag. That’s why it’s critical you heed Warren’s Buffett’s advice and “brace yourself”, before it’s too late. Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Neuronetics (STIM) Receives a Buy from JMP Securities
STIM - Neuronetics, Inc.
Neuronetics Inc STIM Stock Quote
See More Headlines
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Company Calendar

Last Earnings
8/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STIM
Employees
209
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+603.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-37,160,000.00
Pretax Margin
-46.16%

Debt

Sales & Book Value

Annual Sales
$65.21 million
Book Value
$2.10 per share

Miscellaneous

Free Float
27,372,000
Market Cap
$38.97 million
Optionable
Not Optionable
Beta
1.83
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Keith J. SullivanMr. Keith J. Sullivan (Age 65)
    Pres, CEO & Director
    Comp: $1.53M
  • Mr. Stephen J. Furlong M.S.Mr. Stephen J. Furlong M.S. (Age 59)
    Exec. VP, CFO & Treasurer
    Comp: $787.87k
  • Mr. W. Andrew Macan (Age 50)
    Exec. VP, GC, Chief Compliance Officer & Corp. Sec.
    Comp: $646.55k
  • Mr. Rusty Page
    Sr. VP of Operations & Quality
  • Ms. Lisa Metzner-Rosas
    Sr. VP & Chief Marketing Officer
  • Ms. Kara Thornton
    Sr. VP of HR
  • Ms. Sara Grubbs
    Sr. VP & Chief Revenue Officer
  • Mr. Rick Grubbs
    Sr. VP of National Accounts
  • Mr. Todd Cushman
    Sr. VP of Bus. Devel.
  • Mr. Cory S. Anderson
    Sr. VP of R&D and Clinical













STIM Stock - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STIM shares.
View STIM analyst ratings
or view top-rated stocks.

What is Neuronetics' stock price forecast for 2023?

2 brokers have issued 1 year price objectives for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 603.7% from the stock's current price.
View analysts price targets for STIM
or view top-rated stocks among Wall Street analysts.

How have STIM shares performed in 2023?

Neuronetics' stock was trading at $6.87 at the beginning of the year. Since then, STIM stock has decreased by 80.3% and is now trading at $1.35.
View the best growth stocks for 2023 here
.

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our STIM earnings forecast
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) posted its earnings results on Tuesday, August, 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.17. The firm had revenue of $17.61 million for the quarter, compared to analyst estimates of $17.44 million. Neuronetics had a negative trailing twelve-month return on equity of 58.58% and a negative net margin of 46.16%.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.00 million-$18.00 million, compared to the consensus revenue estimate of $17.80 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $1.35.

How much money does Neuronetics make?

Neuronetics (NASDAQ:STIM) has a market capitalization of $38.97 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How many employees does Neuronetics have?

The company employs 209 workers across the globe.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.

This page (NASDAQ:STIM) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -